MariMed Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
MariMed has been growing earnings at an average annual rate of 42.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 28.4% per year.
Anahtar bilgiler
42.6%
Kazanç büyüme oranı
51.7%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 6.0% |
| Gelir büyüme oranı | 28.4% |
| Özkaynak getirisi | -19.8% |
| Net Marj | -11.1% |
| Sonraki Kazanç Güncellemesi | 06 Nov 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Gelir ve Gider Dağılımı
MariMed nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 24 | 156 | -17 | 58 | 0 |
| 31 Mar 24 | 152 | -17 | 55 | 0 |
| 31 Dec 23 | 149 | -16 | 51 | 0 |
| 30 Sep 23 | 146 | -1 | 49 | 0 |
| 30 Jun 23 | 141 | 6 | 45 | 0 |
| 31 Mar 23 | 137 | 9 | 43 | 0 |
| 31 Dec 22 | 134 | 13 | 43 | 0 |
| 30 Sep 22 | 129 | 2 | 44 | 0 |
| 30 Jun 22 | 129 | 2 | 46 | 0 |
| 31 Mar 22 | 128 | 7 | 43 | 0 |
| 31 Dec 21 | 121 | 7 | 39 | 0 |
| 30 Sep 21 | 111 | 18 | 29 | 0 |
| 30 Jun 21 | 91 | 17 | 22 | 0 |
| 31 Mar 21 | 68 | 9 | 19 | 0 |
| 31 Dec 20 | 51 | 2 | 17 | 0 |
| 30 Sep 20 | 36 | -80 | 50 | 0 |
| 30 Jun 20 | 33 | -89 | 48 | 0 |
| 31 Mar 20 | 50 | -84 | 48 | 0 |
| 31 Dec 19 | 46 | -81 | 46 | 0 |
| 30 Sep 19 | 44 | -10 | 16 | 0 |
| 30 Jun 19 | 36 | -7 | 15 | 0 |
| 31 Mar 19 | 13 | -12 | 13 | 0 |
| 31 Dec 18 | 12 | -14 | 12 | 0 |
| 30 Sep 18 | 10 | -7 | 7 | 0 |
| 30 Jun 18 | 8 | -4 | 6 | 0 |
| 31 Mar 18 | 7 | -3 | 5 | 0 |
| 31 Dec 17 | 6 | -1 | 4 | 0 |
| 30 Sep 17 | 6 | 0 | 3 | 0 |
| 30 Jun 17 | 5 | 0 | 2 | 0 |
| 31 Mar 17 | 4 | 0 | 2 | 0 |
| 31 Dec 16 | 4 | 0 | 1 | 0 |
Kaliteli Kazançlar: MRMD is currently unprofitable.
Büyüyen Kar Marjı: MRMD is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MRMD is unprofitable, but has reduced losses over the past 5 years at a rate of 42.6% per year.
Büyüme Hızlandırma: Unable to compare MRMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: MRMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Özkaynak Getirisi
Yüksek ROE: MRMD has a negative Return on Equity (-19.79%), as it is currently unprofitable.